Employer health costs are projected to spike in the upcoming year, forcing many companies that recently expanded coverage of GLP-1 drugs to reverse course.
What happened
A growing number of employers have either dropped or plan to reexamine their coverage of GLP-1s for weight management by 2027, presenting a snag in what has otherwise been a soaring boon for drugmakers and marketers alike.
Why it matters
While most employers will continue to cover the cost of GLP-1s for diabetes, the number of those covering the drugs for weight management dropped from 72 percent in 2025 to 60 percent in 2026, according to a recent survey by Business Group on Health.
That trend is projected to continue, as 10 percent of employers who currently cover GLP-1s for weight loss said they were unlikely to continue that coverage in the future.
All of this means the audience for GLP-1 drugs is more segmented than ever, fracturing the consumer market into those who are eligible for coverage and those who must pay out-of-pocket.
This news brief is based on reporting published by Adweek on 2026-09-09. The original report is linked below.
Adweek
https://www.adweek.com/brand-marketing/cutbacks-in-glp-1-insurance-coverage-are-forcing-marketers-to-pivot/This independent news brief is based on the public source identified above. It is an original summary or translation, not a reproduction of the source article. Rights in source text, research, trademarks and images remain with their respective owners; images are used under the licence or permission identified in the credit. Rights holders may contact rights@goodproductasia.com with evidence of ownership. Verified concerns will be corrected, replaced or removed promptly. This report is not investment, legal, medical or purchasing advice.
